Abstract:

Objective To investigate the clinical value of re-transurethral resection (ReTUR) in the management of non-muscle invasive bladder urothelial cancer. Methods Seventy-six patients with non-muscle invasive bladder urothelial cancer received transurethral resection (TUR) combined with intravesical chemotherapy (single TUR group, n=38) or TUR, ReTUR combined with intravesical chemotherapy (ReTUR group, n=38). The rate of tumor residue after first TUR and rate of restaging after ReTUR in ReTUR group were observed. Patients were followed up after first TUR in two groups, and the rates of tumor recurrence were compared between two groups. Results In ReTUR group, the rate of tumor residue after first TUR was 31.6％, and the rate of restaging after ReTUR was 10.5%. The rate of tumor recurrence in ReTUR group was significantly lower than that in single TUR group (2.8% vs 21.1%, P<0.05). Conclusion Non-muscle invasive bladder urothelial cancer managed by ReTUR may discover residual tumors after first TUR, increase the accuracy of tumor staging, and decrease the rate of tumor recurrence.

Key words: non-muscle invasive bladder urothelial cancer, re-transurethral resection, residual tumor, restaging, recurrence